DE602005018789D1 - Verfahren und kit zur prognose von brustkrebs - Google Patents

Verfahren und kit zur prognose von brustkrebs

Info

Publication number
DE602005018789D1
DE602005018789D1 DE602005018789T DE602005018789T DE602005018789D1 DE 602005018789 D1 DE602005018789 D1 DE 602005018789D1 DE 602005018789 T DE602005018789 T DE 602005018789T DE 602005018789 T DE602005018789 T DE 602005018789T DE 602005018789 D1 DE602005018789 D1 DE 602005018789D1
Authority
DE
Germany
Prior art keywords
breast cancer
prognosis
likelihood
patient
molecular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005018789T
Other languages
English (en)
Inventor
Wen Guo Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiff Biologicals Ltd
Original Assignee
Cardiff Biologicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0417740A external-priority patent/GB0417740D0/en
Priority claimed from GB0426777A external-priority patent/GB0426777D0/en
Application filed by Cardiff Biologicals Ltd filed Critical Cardiff Biologicals Ltd
Publication of DE602005018789D1 publication Critical patent/DE602005018789D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602005018789T 2004-08-10 2005-07-27 Verfahren und kit zur prognose von brustkrebs Active DE602005018789D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0417740A GB0417740D0 (en) 2004-08-10 2004-08-10 Methods and kit for the prognosis of breast cancer
GB0426777A GB0426777D0 (en) 2004-12-07 2004-12-07 Methods and kit for the prognosis of breast cancer
PCT/GB2005/002971 WO2006016110A1 (en) 2004-08-10 2005-07-27 Methods and kit for the prognosis of breast cancer

Publications (1)

Publication Number Publication Date
DE602005018789D1 true DE602005018789D1 (de) 2011-05-26

Family

ID=35044601

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005018789T Active DE602005018789D1 (de) 2004-08-10 2005-07-27 Verfahren und kit zur prognose von brustkrebs

Country Status (15)

Country Link
US (1) US20100035240A1 (de)
EP (1) EP1781814B3 (de)
JP (2) JP5117852B2 (de)
CN (1) CN102443627B (de)
AT (1) ATE454474T1 (de)
AU (1) AU2005271113B2 (de)
CA (1) CA2576113A1 (de)
DE (1) DE602005018789D1 (de)
DK (1) DK1781814T3 (de)
ES (1) ES2339132T7 (de)
GB (1) GB2430741A (de)
HK (1) HK1103422A1 (de)
MX (1) MX2007001640A (de)
PT (1) PT1781814E (de)
WO (1) WO2006016110A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497292B2 (en) 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
KR100786759B1 (ko) * 2006-07-07 2007-12-18 김현기 Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물
CN1919874B (zh) * 2006-09-18 2010-09-08 中国人民解放军军事医学科学院生物工程研究所 一种抗尿激酶型纤溶酶激活剂受体的抗体样分子ATF-Fc融合蛋白及其用途
NZ576149A (en) * 2006-09-29 2012-06-29 Translational Therapeutics Inc Eif4e regulon-based diagnostics
WO2008138868A2 (en) * 2007-05-09 2008-11-20 Traslational Cancer Drugs Pharma, S.L. In vitro diagnosis and/or prognosis of cancer by the analysis of gtpase protein expression
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
US20100081666A1 (en) * 2008-07-14 2010-04-01 Wyeth Src activation for determining cancer prognosis and as a target for cancer therapy
WO2010054379A2 (en) * 2008-11-10 2010-05-14 The United States Of America, As Represensted By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
JP5841047B2 (ja) * 2009-05-08 2016-01-06 ノバルティス アーゲー 線維性障害の診断バイオマーカー
WO2011122857A2 (ko) * 2010-03-30 2011-10-06 서울대학교 산학협력단 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
WO2012131564A1 (en) * 2011-03-27 2012-10-04 Oncostem Diagnostics Pvt. Ltd. Markers for identifying tumor cells, methods and kit thereof
US20140141996A1 (en) * 2011-06-22 2014-05-22 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Cancer
WO2013033609A2 (en) * 2011-08-31 2013-03-07 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of cancer
AU2013209477B2 (en) 2012-01-20 2016-12-08 The Ohio State University Breast cancer biomarker signatures for invasiveness and prognosis
FR2988479B1 (fr) * 2012-03-23 2014-12-19 Hospices Civils Lyon Procede de determination de la susceptibilite aux infections nosocomiales
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
CN103235141A (zh) * 2013-04-27 2013-08-07 上海交通大学医学院附属新华医院 Atf3用于预测膀胱癌转移和判断预后的应用
KR101548830B1 (ko) * 2013-12-30 2015-08-31 가천대학교 산학협력단 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물
EP3093343B1 (de) * 2014-01-10 2020-01-01 Juntendo Educational Foundation Verfahren zur beurteilung des metastatischen potenzials von lymphknoten von endometriumkrebs
PL3536776T3 (pl) * 2014-04-29 2024-03-25 Novartis Ag Nowe komórki kręgowców i sposoby ekspresji rekombinowanej polipeptydu będącego przedmiotem zainteresowania
CN105986024B (zh) * 2015-02-27 2019-10-25 复旦大学附属肿瘤医院 一组用于三阴性乳腺癌预后的基因及其应用
CN104725488A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 关于紧密连接蛋白抑制剂多肽及其应用
CN104725487A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 紧密连接蛋白抑制剂多肽及其应用
TN2017000417A1 (en) 2015-06-05 2019-01-16 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
CN106295244B (zh) * 2015-06-05 2019-09-17 上海交通大学医学院附属瑞金医院 肿瘤诊断标志物的筛选方法、以该方法获得的乳腺癌肺转移相关基因及其应用
JP6820014B2 (ja) * 2015-07-09 2021-01-27 学校法人順天堂 子宮体がんのリンパ節転移能の評価方法
CN106337081B (zh) * 2016-02-02 2020-01-21 中国医学科学院肿瘤医院 FABP4基因的SNP位点rs1054135与三阴型乳腺癌预后的相关性
WO2018074865A2 (ko) * 2016-10-21 2018-04-26 서울대학교병원 유방암 예후 예측용 조성물 및 방법
EP3364190A1 (de) * 2017-02-20 2018-08-22 Panka Cancer Research AG Verfahren zum nachweis von krebs oder krebszellen
WO2018159808A1 (ja) * 2017-03-03 2018-09-07 国立研究開発法人国立がん研究センター 抗ｉｌ－７ｒ抗体の抗体薬物コンジュゲートと、がんまたは炎症を処置することに用いるための、抗ｉｌ－７ｒ抗体と細胞傷害剤との抗体薬物コンジュゲートを含む医薬組成物
CN108504726B (zh) * 2018-03-28 2021-10-26 华南农业大学 采用amf单个孢子微量dna进行pcr预处理的方法
WO2020008097A2 (es) * 2018-07-03 2020-01-09 Universidad De Granada Método de obtención de datos útiles para predecir o pronosticar la supervivencia global y la supervivencia libre de recaídas en el cáncer y composición capaz de modular la actividad de atf4 para el tratamiento del cáncer
CN109620832B (zh) * 2019-01-14 2021-01-01 大连大学 甘氨胆酸在制备抗乳腺增生药物中的应用
KR102280672B1 (ko) * 2019-12-20 2021-07-23 주식회사 베르티스 암의 진단용 조성물
CN114758773A (zh) * 2022-05-25 2022-07-15 四川大学华西医院 一种膀胱癌免疫治疗生物标志物、免疫风险模型及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5759791A (en) * 1989-01-17 1998-06-02 The Johns Hopkins University Cancer related antigen
CA2164498C (en) * 1993-07-09 2007-09-11 Paul A. Price Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices
DE69726884T2 (de) * 1997-02-06 2004-06-03 Genetics Institute, LLC, Cambridge Menschliches sdf-5 protein und diesbezügliche zusammensetzungen
AU2351699A (en) * 1998-01-30 1999-08-16 Brigham And Women's Hospital The human calcium-sensing receptor in the detection and treatment of cancer
DK1131087T4 (da) * 1998-11-13 2009-08-03 Stryker Corp Lindring af prostatacancersymptomer
EP1425302A2 (de) * 2001-01-24 2004-06-09 Protein Design Labs Methoden zur diagnose von brustkrebs sowie methoden zur identifizierung von substanzen, die brustkrebs beeinflussen
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20040086504A1 (en) * 2001-06-21 2004-05-06 Deepak Sampath Cyr61 as a target for treatment and diagnosis of breast cancer
AU2002232563A1 (en) * 2001-12-05 2003-06-23 Genzyme Corporation Compounds for therapy and diagnosis and methods for using same
AU2002366712A1 (en) * 2001-12-20 2003-07-09 The Regents Of The University Of California Genetic markers and methods for the diagnosis, treatment and prevention of tumor metastasis
US20030186248A1 (en) * 2002-03-29 2003-10-02 Erlander Mark G. Interpreting cytological specimens via molecular histological signatures
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure

Also Published As

Publication number Publication date
CA2576113A1 (en) 2006-02-16
JP2008508895A (ja) 2008-03-27
CN102443627B (zh) 2014-10-29
EP1781814B3 (de) 2011-08-31
DK1781814T3 (da) 2010-05-03
JP5634360B2 (ja) 2014-12-03
GB0701676D0 (en) 2007-03-14
JP5117852B2 (ja) 2013-01-16
ATE454474T1 (de) 2010-01-15
EP1781814B1 (de) 2010-01-06
ES2339132T3 (es) 2010-05-17
PT1781814E (pt) 2010-04-12
GB2430741A (en) 2007-04-04
CN102443627A (zh) 2012-05-09
WO2006016110A8 (en) 2006-08-24
ES2339132T7 (es) 2012-03-16
JP2012024095A (ja) 2012-02-09
US20100035240A1 (en) 2010-02-11
MX2007001640A (es) 2007-07-25
EP1781814A1 (de) 2007-05-09
AU2005271113B2 (en) 2010-12-09
AU2005271113A1 (en) 2006-02-16
HK1103422A1 (en) 2007-12-21
WO2006016110A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
ATE454474T1 (de) Verfahren und kit zur prognose von brustkrebs
Rubino et al. Epigenetic regulation of the extrinsic oncosuppressor PTX3 gene in inflammation and cancer
Xiao et al. Analysis of the miRNA–mRNA–lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data
Levine et al. Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes
Scatolini et al. Altered molecular pathways in melanocytic lesions
Tsai et al. Epigenetic regulation of miR‐34b and miR‐129 expression in gastric cancer
Luo et al. Dynamic Alu methylation during normal development, aging, and tumorigenesis
Fenger et al. Overexpression of miR-9 in mast cells is associated with invasive behavior and spontaneous metastasis
US20160160295A1 (en) Non-coding rnas and uses thereof
DK3155126T3 (en) METHOD OF CHOOSING PERSONAL TRIAL TREATMENT FOR CANCER TREATMENT
ATE523786T1 (de) In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens
Liu et al. Identification of aberrant microRNA expression pattern in pediatric gliomas by microarray
NZ548655A (en) Predicting bone relapse of breast cancer using markers
DE602005009406D1 (de) Computerimplementiertes verfahren und computergestütztes system zur validierung von dna-sequenzierungsdaten
RU2016131028A (ru) Композиции, содержащие асимметричную интерферирующую рнк, которые подвергают сайленсингу k-ras, и способы их применения
Rajski et al. BMP2 response pattern in human lung fibroblasts predicts outcome in lung adenocarcinomas
WO2014173905A3 (en) Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides
Tripathi et al. A preliminary sketch of horn cancer transcriptome in Indian zebu cattle
CN108174608B (zh) 用于确定患有i期和ii期透明细胞型肾癌瘤的肾癌患者的复发风险的预后方法以及其试剂盒
ATE530668T1 (de) Verfahren und kits zur brustkrebsprognose
ES2544882T3 (es) Determinación del riesgo de metástasis distante en pacientes con cáncer de pulmón de células no pequeñas en estadio I-IIIA, tratados quirúrgicamente
Dutrow et al. The Human Accelerated Region HACNS1 modifies developmental gene expression in humanized mice
DK1618195T3 (da) Fremgangsmåde til selektiv inhibering af humant N-myc-gen i N-myc-udtrykkende tumorer via antisense- og antigen-peptidnucleinsyrer (PNA)
ATE437235T1 (de) Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix
Campbell et al. Transcription factors expressed in olfactory bulb local progenitor cells revealed by genome-wide transcriptome profiling

Legal Events

Date Code Title Description
8364 No opposition during term of opposition